Senti Biosciences Holdings, Inc. [SNTI] - / Investor merger agreement
Senti Biosciences Holdings, Inc. has entered into a definitive merger agreement with an Investor to purchase newly issued shares of common stock for an aggregate purchase price of $2,500,000 at a per-share price equal to the Minimum Price as defined in Nasdaq Listing Rule 5635(d).
Why this matters
Senti Biosciences Holdings, Inc., incorporated in Delaware, operates in the biological products industry, focusing on developing innovative therapies without diagnostic substances. The company has entered into a definitive merger agreement with an Investor, who has committed to purchasing newly issued shares of Senti's common stock for a total of $2,500,000. This transaction is structured under the Agreement and Plan of Merger dated July 14, 2026, involving Senti Merger Sub, Inc., Senti Holdings, Inc., and Senti Biosciences, Inc. The shares will be purchased at a per-share price equal to the Minimum Price as defined by Nasdaq Listing Rule 5635(d), with the Investor's obligation contingent on the contemporaneous consummation of the closing as outlined in the merger agreement.